Successful treatment of diffuse cutaneous leishmaniasis caused by Leishmania amazonensis
An. bras. dermatol
; 96(5): 602-604, Sept.-Oct. 2021. graf
Article
in English
| LILACS
| ID: biblio-1345132
Responsible library:
BR1.1
ABSTRACT
Abstract Diffuse cutaneous leishmaniasis is a rare universal disease associated with an inadequate host cell immune response, caused by different species infantum, aethiopica, major, mexicana, and others, which presents the challenge of a poor therapeutic response. In Brazil, it is caused by L. amazonensis. A case confirmed by histopathology with an abundance of vacuolated macrophages full of amastigotes and lymphocyte scarcity, identified by RFLP-ITS1PCR and in vitro decrease and exhaustion of the host cell immune response to L. amazonensis antigen, was treated early (3 months after the onset) with Glucantime (2 months) and allopurinol (29 months) with clinical cure, after a follow-up for 30 months after treatment.
Full text:
Available
Collection:
International databases
Health context:
SDG3 - Health and Well-Being
Health problem:
Target 3.3: End transmission of communicable diseases
Database:
LILACS
Main subject:
Leishmania mexicana
/
Leishmaniasis, Diffuse Cutaneous
/
Leishmaniasis, Cutaneous
/
Antiprotozoal Agents
Type of study:
Prognostic study
Limits:
Humans
Country/Region as subject:
South America
/
Brazil
Language:
English
Journal:
An. bras. dermatol
Journal subject:
Dermatology
Year:
2021
Document type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Universidade de Brasília/BR